Endologix (NASDAQ:ELGX) is scheduled to be issuing its quarterly earnings data after the market closes on Tuesday, February 20th. Analysts expect the company to announce earnings of ($0.20) per share for the quarter.
Shares of Endologix (NASDAQ:ELGX) opened at $4.21 on Tuesday. The company has a market capitalization of $344.66, a price-to-earnings ratio of -4.53 and a beta of 0.42. The company has a current ratio of 2.90, a quick ratio of 2.11 and a debt-to-equity ratio of 2.61. Endologix has a 1 year low of $4.00 and a 1 year high of $7.66.
ELGX has been the subject of a number of research reports. BidaskClub cut Endologix from a “buy” rating to a “hold” rating in a research report on Friday, December 15th. Canaccord Genuity reiterated a “hold” rating and set a $5.00 price objective on shares of Endologix in a research report on Wednesday, November 8th. Piper Jaffray Companies reiterated an “overweight” rating on shares of Endologix in a research report on Tuesday, December 12th. Zacks Investment Research cut Endologix from a “hold” rating to a “sell” rating in a research report on Tuesday, January 30th. Finally, Stifel Nicolaus reduced their price objective on Endologix from $6.00 to $5.50 and set a “hold” rating for the company in a research report on Wednesday, November 8th. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and one has assigned a buy rating to the company’s stock. Endologix currently has an average rating of “Hold” and a consensus price target of $5.41.
Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.
Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.